(AVR) Anteris Technologies Global - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 936m USD | Total Return: 89.2% in 12m

Heart Valves, Tissue Scaffolds, Delivery
Total Rating 40
Safety 28
Buy Signal 0.63
Medical Instruments & Supplies
Industry Rotation: +0.7
Market Cap: 936M
Avg Turnover: 6.02M
Risk 3d forecast
Volatility96.5%
VaR 5th Pctl14.7%
VaR vs Median-7.53%
Reward TTM
Sharpe Ratio1.43
Rel. Str. IBD94.2
Rel. Str. Peer Group95.7
Character TTM
Beta2.200
Beta Downside2.649
Hurst Exponent0.635
Drawdowns 3y
Max DD71.46%
CAGR/Max DD0.47
CAGR/Mean DD0.89
EPS (Earnings per Share) EPS (Earnings per Share) of AVR over the last years for every Quarter: "2021-12": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": null, "2024-03": null, "2024-06": null, "2024-09": -1.07, "2024-12": -0.52, "2025-03": -0.61, "2025-06": -0.58, "2025-09": -0.62, "2025-12": -0.75, "2026-03": -0.2774,
Last SUE: -0.02
Qual. Beats: 0
Revenue Revenue of AVR over the last years for every Quarter: 2021-12: 5.830534, 2022-12: 3.200711, 2023-03: 1.071321, 2023-06: 0.809868, 2023-09: 0.598984, 2023-12: 0.544156, 2024-03: 0.766, 2024-06: 0.63154, 2024-09: 0.768981, 2024-12: 0.536112, 2025-03: 0.556, 2025-06: 0.618, 2025-09: 0.429, 2025-12: 0.31, 2026-03: 0.494,
Rev. CAGR: -16.36%
Rev. Trend: -88.0%
Last SUE: -0.48
Qual. Beats: 0

Warnings

Interest Coverage Ratio -1298.0 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Choppy

Tailwinds

Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w

Description: AVR Anteris Technologies Global

Anteris Technologies Global Corp. (AVR) is an Australian-based medical technology company focused on structural heart disease. The firm specializes in the development of the DurAVR transcatheter heart valve system, designed to mimic the natural hemodynamics of a healthy human aortic valve for patients with severe aortic stenosis.

The company’s proprietary ADAPT technology provides a specialized anti-calcification tissue preparation, converting xenograft material into durable bioscaffolds for surgical repair. The structural heart sector is characterized by a shift toward minimally invasive transcatheter aortic valve replacement (TAVR) procedures, which aim to reduce recovery times compared to traditional open-heart surgery.

Complementing its valve technology, Anteris utilizes the ComASUR delivery system, a physician-designed balloon-expandable catheter engineered for precise navigation through cardiac anatomy. For a deeper look at the companys fundamentals, ValueRay provides further data on its market position.

Headlines to Watch Out For
  • FDA approval timeline for DurAVR valve system dictates long-term valuation
  • Clinical trial data milestones for aortic stenosis treatments drive investor sentiment
  • Commercial adoption of ADAPT anti-calcification tissue impacts near-term revenue growth
  • Future capital requirements for large-scale manufacturing increase dilution risk for shareholders
  • Competitive positioning against established structural heart device manufacturers influences market share acquisition
Piotroski VR-10 (Strict) 1.5
Net Income: -95.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.29 > 0.02 and ΔFCF/TA 87.96 > 1.0
NWC/Revenue: 14.7k% < 20% (prev 1.55k%; Δ 13.2k% < -1%)
CFO/TA -0.29 > 3% & CFO -85.0m > Net Income -95.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 20.93 > 1.5 & < 3
Outstanding Shares: last quarter (23.6m) vs 12m ago 0.0% < -2%
Gross Margin: 28.25% > 18% (prev 0.53%; Δ 2.77k% > 0.5%)
Asset Turnover: 1.05% > 50% (prev 4.24%; Δ -3.19% > 0%)
Interest Coverage Ratio: -1.30k > 6 (EBITDA TTM -94.4m / Interest Expense TTM 74.0k)
Altman Z'' -15.00
A: 0.93 (Total Current Assets 286.7m - Total Current Liabilities 13.7m) / Total Assets 294.7m
B: -1.34 (Retained Earnings -393.6m / Total Assets 294.7m)
C: -0.54 (EBIT TTM -96.0m / Avg Total Assets 176.8m)
D: -24.75 (Book Value of Equity -403.8m / Total Liabilities 16.3m)
Altman-Z'' = -27.92 = D
Beneish M -2.43
DSRI: 1.65 (Receivables 231k/189k, Revenue 1.85m/2.49m)
GMI: 1.88 (GM 28.25% / 53.05%)
AQI: 0.15 (AQ_t 0.00 / AQ_t-1 0.00)
SGI: 0.74 (Revenue 1.85m / 2.49m)
TATA: -0.03 (NI -95.3m - CFO -85.0m) / TA 294.7m)
Beneish M = -2.43 (Cap -4..+1) = BBB
What is the price of AVR shares?

As of May 27, 2026, the stock is trading at USD 9.08 with a total of 1,613,770 shares traded.
Over the past week, the price has changed by +19.95%, over one month by +60.42%, over three months by +43.22% and over the past year by +89.17%.

Is AVR a buy, sell or hold?

Anteris Technologies Global has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy AVR.

  • StrongBuy: 3
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the AVR price?
Analysts Target Price 16 76.2%
Anteris Technologies Global (AVR) - Fundamental Data Overview as of 27 May 2026
Market Cap USD = 936.4m (936.4m USD * 1.0 USD.USD)
P/S = 505.906
P/B = 3.3596
Revenue TTM = 1.85m USD
EBIT TTM = -96.0m USD
EBITDA TTM = -94.4m USD
Long Term Debt = 2.42m USD (estimated: total debt 3.73m - short term 1.31m)
Short Term Debt = 1.31m USD (from shortTermDebt, last quarter)
Debt = 5.34m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.61m
Net Debt = -277.9m USD (calculated: Debt 5.34m - CCE 283.2m)
Enterprise Value = 658.6m USD (936.4m + Debt 5.34m - CCE 283.2m)
Interest Coverage Ratio = -1.30k (Ebit TTM -96.0m / Interest Expense TTM 74.0k)
EV/FCF = -7.60x (Enterprise Value 658.6m / FCF TTM -86.7m)
FCF Yield = -13.16% (FCF TTM -86.7m / Enterprise Value 658.6m)
 FCF Margin = -4.68k% (FCF TTM -86.7m / Revenue TTM 1.85m)
 Net Margin = -5.15k% (Net Income TTM -95.3m / Revenue TTM 1.85m)
 Gross Margin = 28.25% ((Revenue TTM 1.85m - Cost of Revenue TTM 1.33m) / Revenue TTM)
Gross Margin QoQ = -9.92% (prev -65.81%)
Tobins Q-Ratio = 2.23 (Enterprise Value 658.6m / Total Assets 294.7m)
Interest Expense / Debt = 1.38% (Interest Expense 74.0k / Debt 5.34m)
Taxrate = 21.0% (US default 21%)
NOPAT = -75.9m (EBIT -96.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 20.93 (Total Current Assets 286.7m / Total Current Liabilities 13.7m)
Debt / Equity = 0.02 (Debt 5.34m / totalStockholderEquity, last quarter 278.4m)
 Debt / EBITDA = 2.94 (negative EBITDA) (Net Debt -277.9m / EBITDA -94.4m)
 Debt / FCF = 3.21 (negative FCF - burning cash) (Net Debt -277.9m / FCF TTM -86.7m)
 Total Stockholder Equity = 76.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.92% (Net Income -95.3m / Total Assets 294.7m)
RoE = -20.27% (Net Income TTM -95.3m / Total Stockholder Equity 470.2m)
RoCE = -20.32% (EBIT -96.0m / Capital Employed (Equity 470.2m + L.T.Debt 2.42m))
 RoIC = -29.17% (negative operating profit) (NOPAT -75.9m / Invested Capital 260.2m)
 WACC = 13.65% (E(936.4m)/V(941.8m) * Re(13.72%) + D(5.34m)/V(941.8m) * Rd(1.38%) * (1-Tc(0.21)))
Discount Rate = 13.72% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: -73.03 | Cagr: -17.09%
 [DCF] Fair Price = unknown (Cash Flow -86.7m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.02 | # QB: 0
Revenue Correlation: -88.01 | Revenue CAGR: -16.36% | SUE: -0.48 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.22 | Chg30d=-19.73% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.25 | Chg30d=-8.21% | Revisions=+20% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.08 | Chg30d=-24.10% | Revisions=-14% | GrowthEPS=+57.5% | GrowthRev=+410.6%
EPS next Year (2027-12-31): EPS=-1.10 | Chg30d=-13.18% | Revisions=-20% | GrowthEPS=-1.4% | GrowthRev=+43.9%
[Analyst] Revisions Ratio: +20%